Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. develops drug delivery and consumer-product dosing, dispensing and protection technologies for pharmaceutical, beauty, food, beverage, personal care and home care markets. News about ATR commonly covers operating results across Pharma, Beauty and Closures, demand trends in prescription drug delivery, biologics, injectables, nasal delivery, fragrance dispensing and closure applications.
Company updates also include product introductions such as inverted lidless dispensing closures using SimpliSqueeze® valve technology, Aptar Pharma delivery systems used in clinical-stage nasal therapies, Aptar Digital Health partnerships, dividend declarations, share repurchases and investor presentations.
Aptar (NYSE:ATR) announced its proprietary multidose intranasal delivery system is being used in LTR Pharma's Phase II study of SPONTAN®, an investigational intranasal spray for erectile dysfunction. Aptar teams Nanopharm and Noble support formulation, analytical testing, human factors and risk management to advance clinical and regulatory readiness.
The announcement notes first-patient dosing in the Phase II study and emphasizes Aptar Pharma's role providing dosing accuracy, stability data and usability validation to support development.
Aptar (NYSE: ATR) will present at two investor conferences in early 2026. Stephan Tanda, President and CEO, will speak at the Bank of America Securities 2026 Global Agriculture and Materials Conference on Feb 25, 2026 at 9:45 a.m. ET. Vanessa Kanu, EVP and CFO, will speak at the Raymond James 2026 Institutional Investors Conference on Mar 3, 2026 at 1:05 p.m. ET. A live audio webcast and presentation materials will be available in the Investors section of the company website.
AptarGroup (NYSE:ATR) reported fourth quarter 2025 results: reported sales $963M (+14% YoY), core sales +5%, fourth-quarter reported net income $74M (−26%) and reported EPS $1.13 (−24%). Adjusted EPS was $1.25 and adjusted EBITDA margin was 19.8% (down from 23.0%).
For full year 2025, reported sales were $3.78B (+5%), reported EPS $5.89 (+7%), cash flow from operations $570M, free cash flow $303M, and the Board approved a new $600M share repurchase authorization. Q1 2026 adjusted EPS guide: $1.13–$1.21.
Aptar (NYSE: ATR) announced a $0.48 per share quarterly cash dividend, payable on February 25, 2026 to stockholders of record as of February 4, 2026. The company will host a conference call on February 6, 2026 at 8:00 a.m. Central Time to discuss fourth-quarter and full-year 2025 results, with a live webcast and limited-time replay available on the investor website.
The Board also set the 2026 Annual Meeting of Stockholders for a virtual session on May 6, 2026 at 9:00 a.m. Central Time, with a record date for voting of March 13, 2026. Additional meeting access details will be provided closer to the event.
Aptar (NYSE: ATR) achieved an “A” score on the CDP Climate Change Assessment for the second consecutive year, placing the company among the top 4% of nearly 20,000 scored organizations based on its 2025 disclosure. Aptar reported actions to cut emissions, mitigate climate risks and advance a low-carbon economy, supported by SBTi-validated Scope 1 and Scope 2 targets aligned to 1.5°C by 2030, a Scope 3 target, renewable electricity goals, and Power Purchase Agreements in Europe and the US. The company also improved TCFD disclosures and received ISO 14046 certification, reflecting increased renewable purchases and GHG reductions across scopes.
Aptar (NYSE: ATR) announced that its nasal delivery devices LuerVax and Spray Divider are being used in CastleVax’s Phase II trial of CVAX-01, an intranasal COVID-19 vaccine candidate.
The trial will enroll about 200 U.S. adults, including high-risk and 65+ participants, and follow them for six months to compare safety, tolerability and systemic and mucosal immune responses versus an FDA-approved injectable mRNA vaccine. Aptar cites its regulatory and technical support, device/formulation expertise, and Pharma Services capabilities to support development and accelerate time-to-market.
Aptar (NYSE: ATR) outlined its eye care portfolio highlighting the new Beat the Blink™ delivery system designed to improve dosing precision by delivering horizontal drops and protecting preservative-free formulas with a tip seal. Beat the Blink is in an exclusive partnership with Bausch and Lomb and commercial availability is estimated after development and industrialization in 24–36 months. Aptar also described its Ophthalmic Squeeze Dispenser (OSD) with Tip-Seal microbial testing, APF preservative-free pumps and the recyclable APF Futurity metal-free nasal system, plus digital healthcare solutions for patient monitoring and eye care support.
Aptar (NYSE: ATR) announced its 2026 quarterly conference call schedule with dates and times for earnings-related calls and accompanying press release timing.
Press release dates (after NYSE close) and conference calls (all at 8:00 a.m. CT):
- 4Q & Annual 2025: Press release Feb 5, 2026 — Call Feb 6, 2026
- 1Q 2026: Press release Apr 30, 2026 — Call May 1, 2026
- 2Q 2026: Press release Jul 30, 2026 — Call Jul 31, 2026
- 3Q 2026: Press release Oct 29, 2026 — Call Oct 30, 2026
Calls are ~one hour, held in Central time, available live via webcast at the company investor website with replay access on the Investors page. Any updates will be announced in later releases.
Aptar Digital Health (NYSE:ATR) announced a partnership with ŌURA to integrate Migraine Buddy® with Oura Ring biometric data on January 6, 2026. The integration connects Migraine Buddy’s symptom tracking, reporting, and coaching with continuous Oura metrics including sleep, heart rate variability, temperature trends, and cycle insights.
The joint solution aims to give millions of users—especially women—personalized visibility into migraine patterns and potential triggers to support better self‑management.
Aptar (NYSE:ATR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Stephan Tanda, President and CEO, will present at 11:15 a.m. Eastern; Vanessa Kanu, EVP and CFO, and Gael Touya, President Aptar Pharma, will also be available.
A live audio webcast and presentation materials will be accessible in the Investors section of the company website at www.aptar.com.